Ahmet Demirkazik

Ankara University, Engüri, Ankara, Turkey

Are you Ahmet Demirkazik?

Claim your profile

Publications (70)166.62 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the present study was to obtain the first data for the phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA) mutation frequency among nonsmall-cell lung cancer (NSCLC) patients in Turkey. All exons of the PIK3CA gene were investigated by sequence analysis in 40 NSCLC tumor tissue samples. The 1634A>C mutation, which has previously been identified in many cancers including NSCLC, was identified in three tumor tissue samples in the present study. Interestingly, a second mutation (1658_1659delGTinsC) was also identified in these patients. The concurrence of these two mutations has been reported as the Cowden syndrome, which is known to be a cancer predisposition syndrome. This finding is important since it may be an indicator of the underlying cancer predisposition syndrome in NSCLC patients. Moreover, four novel mutations were identified in the present study. However, in vitro studies are required to evaluate the effects of these mutations on kinase activation. The high frequency of PIK3CA mutations exerts important clinical implications for targeted therapy. This finding indicates that therapeutic agents targeting the phosphatidylinositol 3-kinase (PI3K) would be beneficial in the NSCLC subpopulation.
    No preview · Article · Jun 2015 · Genetic Testing and Molecular Biomarkers
  • [Show abstract] [Hide abstract]
    ABSTRACT: Identification of biomarkers used for the prognostic evaluation of non-small cell lung cancer (NSCLC) patients is important. The aim of this study was to evaluate the potential prognostic value of XRCC1, ERCC1, ERCC2, and TP53 single nucleotide polymorphisms (SNPs) in completely resected NSCLC patients. In total, 130 patients, surgically treated for NSCLC between 2000 and 2012, were included. An analysis of SNPs from peripheral blood cells was performed by polymerase chain reaction. XRCC1 Arg399Gln, ERCC1 Asn118Asn, ERCC2 Lys751Gln, and TP53 Arg72Pro polymorphisms were evaluated in conjunction with clinical and pathological parameters and survival. Kaplan-Meier method and Cox regression analysis were used. Median age rate was 59.3, ranging between 36 and 78 years. Median relapse-free survival duration (RFS) was found as 46.2 months. In those with ERCC2 CC allele, median RFS was detected as 28.3 months (95 % confidence interval (CI), 20.8-35.8), 46.9 months in those with CT heterozygous (95 % CI, 18.6-75.2), and 80.1 months for those with TT mutant allel (95 % CI, 33.0-127.2). Median RFS was seen to be longer in mutant group and also statistically significant (P = 0.018). Additionally, upon evaluating CC normal group with CT + TT alleles including mutant alleles, median RFS was found as 56.5 months (95 % CI, 24.6-88.4) in CT + TT group, and this was statistically significant (P = 0.005) Also, median RFS was 15.1 months in those including ERCC2 CC allele and 56.5 months in CT + TT allele in the group with no adjuvant treatment (P = 0.001). In conclusion, our study showed that ERCC2/XPD polymorphism is an independent prognostic factor in operated NSCLC patients, and these findings should be supported with prospective studies.
    No preview · Article · Jan 2015 · Tumor Biology

  • No preview · Article · Jul 2014 · Journal of endocrinological investigation

  • No preview · Article · May 2014 · European Journal of Cancer
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the study was to evaluate EGFR (exon 19 deletion, exon 21 L858R point mutation), KRAS and braf mutation rates besides their relationship with survival and response to the treatment in non small cell lung cancer (NSCLC). We evaluated 513 NSCLC patients followed-up between January 2004 and November 2009 according to our registration data, retrospectively. Only 42 advanced stage NSCLC patients had enough tumor tissue material in paraffin blocks for all mutation analysis. The patients were evaluated retrospectively for clinicopathological features, EGFR, KRAS and BRAF mutations, erlotinib treatment, time to progression (TTP) and overall survival (OS). Mutation rates were as 7.14% (two patients) for EGFR exon 19 deletion; 4.76% (one patient)for KRAS codon 61 deletion and 2.38% for BRAF V600E mutation. They had neither EGFR exon 21 point mutation nor different mutations together. Median follow-up was 26 months (5-83) for all patients. It was 43 months (23-83) for the patients who had erlotinib and 23 months (5-61) for those who did not. Ten (23.8%) patients had erlotinib. There was significant survival difference between the patients taking erlotinib and the others (28 ± 3 months versus 15 ± 4 months, p= 0.05). TTP and OS were longer in the patients who had mutations, however the difference was not significant (p= 0.119 and p= 0.06). To our knowledge, this is the first study evaluating EGFR, KRAS and BRAF mutations in advanced stage NSCLC in Turkey.
    No preview · Article · Jan 2014 · UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm that originates from follicular dendritic cells in lymphoid follicles. FDCS has been increasingly reported in recent years. However, data on FDCS are mostly based on single case reports or case series and its natural history and standard treatment are not clear. To increase the understanding of this rare disease, we report our experience of three cases of FDCS with an analysis of the morphological and immunophenotypic characteristics, clinical course, treatment options and response to treatment. In addition, we reviewed the literature on FDCS.
    Full-text · Article · Jun 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The ABO blood groups and Rh factor may affect the risk of lung cancer. Materials and methods: We analyzed 2,044 lung cancer patients with serologically confirmed ABO/Rh blood group. A group of 3,022,883 healthy blood donors of Turkish Red Crescent was identified as a control group. We compared the distributions of ABO/Rh blood group between them. Results: The median age was 62 years (range: 17-90). There was a clear male predominance (84% vs. 16%). Overall distributions of ABO blood groups were significantly different between patients and controls (p=0.01). There were also significant differences between patients and controls with respect to Rh positive vs. Rh negative (p=0.04) and O vs. non-O (p=0.002). There were no statistically significant differences of blood groups with respect to sex, age, or histology. Conclusions: In the study population, ABO blood types were associated with the lung cancer. Having non-O blood type and Rh-negative feature increased the risk of lung cancer. However, further prospective studies are necessary to define the mechanisms by which ABO blood type may influence the lung cancer risk.
    No preview · Article · May 2013 · Asian Pacific journal of cancer prevention: APJCP
  • Y Urun · H Akbulut · A Demirkazik · F Cay Senler · G Utkan · H Onur · F Icli
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Although influenza and pneumococcal vaccinations for high-risk populations are recommended by current guidelines, vaccination coverage rate (VCR) is still low in patients with malignancies and the family members living with them. Methods: During the 2011-2012 seasonal influenza (SI), we surveyed 359 patients with solid or hematological malignancies Data were recorded in an especially designed questionnaire after face to face interview. Results: The median patient age was 57 years (range 18-90) and 177 (49.3%) patients were female. Overall vaccination rate was 17% and 4.2% for influenza and pneumococcus, respectively. VCR among family members was 21.2%. The most common causes for not getting vaccinated were lack of knowledge for indication by the patients (33.5%), getting chemotherapy (22.1%), fear of side effects (12.5%), lack of efficacy (12.1%), and not advised by the attending physician (5.9%). Conclusion: VCR was very low among patients with cancer and their family members. To eliminate misconceptions and improve vaccination coverage in this population, educational programs for patients and for physicians focusing on safety and efficacy of vaccine are needed.
    No preview · Article · Apr 2013 · Journal of B.U.ON.: official journal of the Balkan Union of Oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Previous studies have observed an association between ABO blood group and risk for certain gastrointestinal malignancies, including pancreatic and gastric cancer. However, it is unclear whether there is such an association with colorectal cancer (CRC). In this study, possible relationships between ABO blood groups and Rh factor and KRAS status in patients with CRC were investigated. Materials and methods: In 1,620 patients with CRC, blood group and Rh factor were examined and compared with the control group of 3,022,883 healthy volunteer blood donors of the Turkish Red Crescent between 2004 and 2011. The relationship of blood groups with wild type K-ras status was also evaluated. Results: Overall distributions of ABO blood groups as well as Rh factor were comparable between patients (45% A, 7.2% AB, 16.4% B, 31.4% O, and 87.2% Rh+) and controls (42.2% A, 7.6% AB, 16.3% B, 33.9% O, and 87.7% Rh+) (p=0.099). However, there were statistically significant difference between patients and controls with respect to O vs. non O blood group (p=0.033) and marginally significant difference for A vs. non-A blood group (p=0.052). Among patients, the median age was 62 (range 17-97), 58.1% were male. There were no statistically significant differences respect to sex and K-ras status. Conclusion: In present study, the ABO/Rh blood groups were statistically significantly associated with the risk of CRC. There were no relationship between K-ras status and ABO blood group and Rh factor. However further studies with larger numbers of patients are needed to establish the role of blood groups and to define the mechanisms by which ABO blood type affect CRC.
    No preview · Article · Dec 2012 · Asian Pacific journal of cancer prevention: APJCP
  • [Show abstract] [Hide abstract]
    ABSTRACT: The role of genetic factors in the development of cancer is widely accepted. Data on the role of ABO blood group and Rh factor in breast cancer is inconclusive. The aim of this study was to investigate the presence of a possible association between HER2 (+) breast cancer in Turkish women and ABO blood groups and Rh factor. In 294 female patients with HER2 (+) breast cancer, ABO blood groups and Rh factor were examined. The relationship of blood groups with age, menopausal status, and family history of cancer, estrogen receptor (ER), progesterone receptor (PR) and HER2 status of these patients was evaluated. Blood groups distribution of 22,821 healthy blood donors was also assessed and compared with the patients' blood groups distribution. The median patient age was 47 years (range 20-80) and 56% of the patients were premenopausal. ER and PR were positive in 50 and 60% of the patients, respectively. Overall, the ABO blood group distribution of the 294 HER2 (+) breast cancer patients was similar to that of the healthy blood donors (p=0.36). Likewise there was no correlation between blood type and ER, PR and menopausal status. Rh (-) patients had more frequent family cancer history and this difference was significant for patients with blood group B Rh (-) and O Rh (-) (p = 0.04). In the present study we didn't find any relationship between HER2 status and ABO blood group and Rh factor. However, further studies with larger number of patients are needed to establish the role (if any) of blood groups in patients with breast cancer.
    No preview · Article · Oct 2012 · Journal of B.U.ON.: official journal of the Balkan Union of Oncology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antimetabolites may cause severe toxicity and even toxic death in cancer patients. Our aim was to evaluate the relationship between antimetabolite toxicity and pharmacogenetics in patients with severe clinical toxicity or alanine transaminase (ALT) elevation after fluorouracil (5FU), capecitabine or methotrexate administration. Cancer patients with severe antimetabolite toxicity were evaluated for methylenetetrahydrofolate reductase (MTHFR) gene C667T, thymidilate synthase (TS) gene 5' UTR variable number of tandem repeats (VNTR), dihydroprymidine dehydrogenase (DPYD) gene IVS14+1G/A, Xeroderma pigmentosum (XPD) gene Lys751Gln and X-ray repair cross-complementing group 1 (XRCC1) gene Arg399Gln polymorphisms. Eighteen patients were enrolled, with a male/female ratio of 0.8. They had osteosarcoma in methotrexate group (n=7), gastrointestinal malignancies in 5FU group (n=9) and breast cancer in the capecitabine group (n=2). Mucositis and dermatitis occurred in all groups, together with ALT elevation in the methotrexate group and 2 toxic deaths were encountered. DPYD, TS, MTHFR, XPD and XRCC1 gene polymorphism rare allele frequencies were observed to be higher than in the general population. Pharmacogenetics might contribute to tailored therapy.
    Full-text · Article · Apr 2012 · Asian Pacific journal of cancer prevention: APJCP
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this retrospective study, it was aimed whether albumin infusion is benefical or not in terminally ill hospitalized hypoalbuminemic cancer patients. Between March 2000 and 31 March 2003, the medical records of 27 terminally ill hypoalbuminemic cancer patients who had albumin infusion(Albumin receiving group-ARG), were retrospectively analysed. This grup was matched (1:1) with 27 terminally ill cancer patients who had no albumin infusion (Albumin not receiving group-ANRG), according to age, sex, ECOG PS, diagnosis and the number of metastatic sites. ARG was compared with ANRG, in regard to the changes of pulse rate, blood pressure, in the levels of serum BUN, creatinin, sodium, total protein, and albumin before albumin infusion and 48 hours after albumin infusion, and documented and/or clinical infections after albumin infusion, hospitalization duration, the rate of exitus in hospital and overall survival. There was no difference in patient characteristics between two groups. Likewise, the groups were not different from each other in terms of the changes of puls rate, blood pressure, in the levels of serum BUN, creatinin, sodium, and documented and/or clinical infections after albumin infusion (p> 0.05). There was a significant increase in the levels of serum total protein and albumin in ARG (p< 0.05). The rate of exitus in hospital is not different between two groups. The median duration of hospitalization was longer in ANRG (p= 0.022). The overall survival was significantly better in ANRG (p= 0.018). Albumin infusion is not benefical in terminally ill hypoalbuminemic cancer patients. Furthermore, it was found that the survival was significantly worse in patients receiving albumin.
    No preview · Article · Jan 2012 · UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Changes occur in the oropharyngeal flora of the cancer patients due to disease and treatment related factors. In this study, bacte-rial and candidal colonizations were evaluated in 119 cancer patients from the two clinics (Ibni Sina Hospital is old clinic and Cebe-ci Hospital is new clinic) of the Medical Oncology Department of Ankara University Medical Faculty. Throat swabs and cultures we-re obtained from all patients on days 0, 4 and 7 of admission. The clinical parameters that can effect colonization like age, sex, use of steroids and antibiotics, chemotherapy, catheterization/TPN (total parenteral nutrition) procedures, ECOG performance status and number of admissions were recorded. The distribution of detected microorganisms and the differences in subsequent days were evaluated. There were no significant differences between two hospitals with regard to bacterial and candidal colonizations on the 1st, 4th and 7th days. The performance status, catheterization/TPN procedures, usage of antibiotics and chemotherapy are found to be the significant clinical parameters that can effect colonizations. ÖZET Kanser Hastalar›nda Orofaringeal Kandida ve Bakteriyel Kolonizasyonun Özellikleri Kanser hastalar›nda hastal›¤a ve tedavilere ba¤l› faktörler nedeniyle, orofaringeal florada de¤ifliklikler olmaktad›r. Bu çal›flmada, An-kara Üniversitesi T›p Fakültesi T›bbi Onkoloji Bilim Dal›'n›n iki klini¤inden (‹bni Sina Hastanesi ve Cebeci Hastanesi) toplam 119 has-tada bakteriyel ve kandida kolonizasyonlar› incelendi. ‹lk 24. saatte, 4.gün ve 7.günde bo¤azdan sürveyans kültürü amaç-l› sürüntü al›nd›. Yafl, cinsiyet, steroid, antibiyotik kullan›m›, kemoterapi, kateter/total parenteral nütrisyon uygulamalar›, ECOG perfor-mans statusu ve daha önceki yat›fl say›s› gibi kolonizasyonu etkileyebilecek klinik parametreler kaydedildi. Saptanan mikroorganiz-malar›n da¤›l›m›na, günlere göre de¤iflikli¤ine bak›ld›. ‹bni Sina ve Cebeci Hastaneleri aras›nda hem bakteriyel hem de kandida kolo-nizasyonu aç›s›ndan 1, 4. ve 7. günlerde anlaml› farkl›l›k saptanmad›. Kolonizasyonu etkiledi¤i belirlenen en önemli klinik özellikler per-formans statusu, kateter-TPN (total parenteral nütrisyon), antibiyotik ve kemoterapi kullan›m› idi.
    Full-text · Article · Jan 2012

  • No preview · Article · Sep 2011 · European Journal of Cancer

  • No preview · Article · Sep 2011 · European Journal of Cancer
  • B. Yalcin · N. Suna · M. Dogan · Y. Urun · N. Özdemir · U. Gonullu · N. Zengin · G. Utkan · A. Demirkazik · F. Igli

    No preview · Article · Sep 2011 · European Journal of Cancer
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study was designed to assess the tolerability of chronomodulated infusion chemotherapy, individualized by the rhythm of peripheral blood cells. Twenty patients with metastatic gastric cancer were randomized to chronotherapy or day-time arms of 5-fluorouracil (FU) (600 mg/m2, 8 h inf.d1–5) and folinic acid (FA) (20 mg/m2, iv, d1–5) in the first cycle and crossed-over to the other arm in the following cycles. Ten of 18 evaluable patients were assigned to chronotherapy arm and eight to day-time in the first cycle. Although there was no significant difference between two arms on enrollment, chronotherapy arm yielded an improvement of 45% of QLQ-C30 scores (p = 0.021) and the day-time arm had 11% improvement (p = 0.575). After the crossing-over, chronotherapy arm, again, had a significant improvement in QLQ-C30 scores, compared to the day-time arm (14% vs. −18%, p = 0.001, respectively). Mucositis/diarrhea was significantly higher in the day-time arm compared to chronotherapy arm (p = 0.015). In conclusion, chronomodulated infusion of 5-FU might improve the quality of life.
    Full-text · Article · Nov 2010 · Biological Rhythm Research
  • [Show abstract] [Hide abstract]
    ABSTRACT: Kaposi sarcoma (KS) is a mesenchymal tumor originating from lymphatic endothelial cells. Immunosuppressive patients have higher risk for KS. HHV-8 has a role in immunopathogenesis of KS. Aim Evaluation of demographical properties with tumor characteristics and treatment modalities of KS. Histopathologically documented KS patients were evaluated retrospectively. Anti-HIV seroprevalence was also evaluated with patient and tumor characteristics besides treatment regimens. Fifty-one patients were included between September 1998 and February 2009. Male/female ratio was 3.25 (39/12). Median age was 68 (31-94). Lower extremity was the most common site whereas excisional biopsy was the most common diagnostic procedure. Smoking rate was 42.8%. Twenty percent had family history for cancer. Anti- HIV seropositivity rate was 1.9%. Thirty eight percent had local monotherapy, and radiotherapy was most common (26%). Multidisciplinary approach rate was 44%. Most of them had surgery and radiotherapy combination. Two-third of the patients had radiotherapy alone or with other modalities. Rates were as 12% for chemotherapy and 6% for interferon. Vincristine-bleomycin-doxorubicin combination was the most preferred regimen (60%). Male patients in the sixth decade seem to have higher risk for KS. Smoking rate was almost as high. Local therapy might be sufficient in most of the patients. However, we may also consider systemic chemotherapy for selected patients, including vincristine, bleomycin and doxorubicin.
    No preview · Article · Sep 2010 · Clinical and Translational Oncology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the study was to evaluate the relationship among leucocytosis, thrombocytosis and serum vascular endothelial growth factor (VEGF) levels and their prognostic value in patients with NSCLC. Fifty-five patients with histopathological and/or cytopathological diagnosed NSCLC were enrolled into the study. The patients were grouped as patients with leuco-cytosis (>10.000/mm 3) and/or thrombocytosis (>400.000/mm 3) (group 1), and others with none of them as a control group (group 2). Serum VEGF levels were measured by ELISA. Group 1 had three subgroups: patients with leucocytosis (group 1a), patients with thrombocytosis (group 1b) and patients with both of them (group 1c). Survival of the patients were analysed by Kaplan-Meier method. There was no survival difference between group 1 and 2, although there was a trend in favour of control group. The patients with higher levels of serum VEGF had a shorter survival than others who had lower lev-els, when the mean VEGF level of control group (206 pg/ml) was defined as cut-off value in group 1. The patients with leu-cocytosis and thrombocytosis had significantly higher VEGF levels when compared with control group (p= 0.022). No sur-vival difference was observed for groups 1a, 1b and 1c when compared with control group. In conclusion, serum VEGF lev-els were significantly higher in patients who had leucocytosis and/or thrombocytosis although leucocytosis and/or throm-bocytosis could not have been shown as a prognostic factor in patients with NSCLC. The association between serum VEGF and leucocytosis/thrombocytosis could not have been concluded as a cause or result.
    Full-text · Article · Mar 2010 · UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi

  • No preview · Article · Nov 2009 · The Breast Journal

Publication Stats

486 Citations
166.62 Total Impact Points

Institutions

  • 1995-2015
    • Ankara University
      • • Department of Medical Oncology
      • • Department of Internal Medicine
      Engüri, Ankara, Turkey
  • 1998-2005
    • Sina Hospital
      Mashad, Razavi Khorasan, Iran
  • 1993-1997
    • Ibn Sina Hospital Dhanmondi
      Baghdād, Mayorality of Baghdad, Iraq